Oligomerix, Inc
Oligomerix is a privately held clinical stage biotechnology company focused on developing disease-modifying, oral small molecule therapeutics targeting protein aggregation in neurodegenerative diseases such as Alzheimer’s disease and rare tauopathies. The company aims to improve patients' lives by discovering and developing simple-to-use therapeutics that inhibit tau self-association, thereby preventing disease progression. With a proprietary platform technology, a strong IP position, and an experienced management team, Oligomerix is advancing its lead candidate OLX07010 and other compounds through clinical development.
Industries
Nr. of Employees
small (1-50)
Oligomerix, Inc
2 Westchester Park Drive, Suite 208, White Plains, NY 10604
Patents
Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
US-12331043-B2
View DetailsQuinazolinones that inhibit the formation of tau oligomers and their method of use
US-11472776-B2
View DetailsBenzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
US-11306075-B2
View Details
Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
US-12331043-B2
View DetailsQuinazolinones that inhibit the formation of tau oligomers and their method of use
US-11472776-B2
View DetailsBenzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
US-11306075-B2
View DetailsProducts
Lead brain-penetrant oral small-molecule tau self-association inhibitor (lead candidate) and second-generation series
A development-stage oral small-molecule program that inhibits tau protein self-association; includes a lead clinical candidate and follow-on analog series intended for treatment of Alzheimer’s disease and other tauopathies.
Lead brain-penetrant oral small-molecule tau self-association inhibitor (lead candidate) and second-generation series
A development-stage oral small-molecule program that inhibits tau protein self-association; includes a lead clinical candidate and follow-on analog series intended for treatment of Alzheimer’s disease and other tauopathies.
Services
Preparation of program data packages and engagement to enable partnering, licensing or acquisition of therapeutic programs.
Provision of preclinical efficacy, exposure/safety studies and biomarker assay development to support translational advancement of CNS small-molecule programs.
Lead optimization, process development, and technology transfer support for clinical supply and scalable manufacturing of small molecules.
Preparation of program data packages and engagement to enable partnering, licensing or acquisition of therapeutic programs.
Provision of preclinical efficacy, exposure/safety studies and biomarker assay development to support translational advancement of CNS small-molecule programs.
Lead optimization, process development, and technology transfer support for clinical supply and scalable manufacturing of small molecules.
Expertise Areas
- Tau-targeted small-molecule drug discovery
- Preclinical in vivo efficacy and pharmacology (tauopathy models)
- Biomarker and assay development for CNS therapeutics
- Early-phase clinical development (Phase I) and IND transition
Key Technologies
- Small-molecule drug discovery for protein aggregation
- Proprietary aggregation screening assay
- In vivo tauopathy mouse models
- Biomarker assay platforms